Novo Nordisk alleges fraud after US$1.3 billion deal to buy hypertension drug from Singapore-based KBP Biosciences
Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Novo Nordisk A/S to Contact the Firm Today!
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Asia One13h
Singapore company sued by Novo Nordisk over $1.7b hypertension drug deal
Novo Nordisk is seeking up to US$830 million (S$1.1 billion) in damages from KBP Biosciences, according to a ruling by a ...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...